Huang Xueqin, Xu Peng, Long Guangwen, Huang Feihong, Zhang Qian, Yang Xiulin, Sun Hongpeng, Ji Chunling, Liu Wang
Department of Respiratory Medicine, 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Cangshan Campus, Fuzhou, 350007, Fujian Province, China.
Department of Emergency, Wuhan Brain Hospital, General Hospital of the YANGTZE River Shipping, Wuhan, Hubei, China.
Hereditas. 2025 Apr 26;162(1):71. doi: 10.1186/s41065-025-00436-1.
The high mortality rate of ARDS is closely related to pulmonary fibrosis (PLF), and the degree of pulmonary fibrosis affects the prognosis of ARDS. Numerous studies indicated the abnormal expression of miRNAs in the pathogenesis of various lung diseases, such as ARDS and PLF. This study aimed to explore the expression of serum miR-6515-5p and its clinical performance in ARDS complicated with PLF.
RT-qPCR analysis was employed to measure miR-6515-5p levels within the serum specimens from ARDS patients who either had PLF or did not. Receiver Operating Characteristics (ROC) curve was conducted to evaluate the diagnostic value of miR-6515-5p. To analyze the risk factors linked with the development of PLF in ARDS patients, logistic regression analysis was conducted. Kaplan-Meier curve was conducted to assess the prognostic value of miR-6515-5p in predicting the outcome of ARDS patients with PLF. Multivariate COX regression analysis was performed to identify the PLF-related risk factors associated with outcomes.
Serum miR-6515-5p was downregulated in ARDS patients, especially in patients suffering from PLF. miR-6515-5p expression can distinguish ARDS patients from healthy individuals and related to the occurrence of PLF. Most patients with low miR-6515-5p expression had low FVC and DLCO, as well as high Murray score and APACHE II score. Moreover, miR-6515-5p expression has a certain high value in differentiating ARDS patients with PLF from those without PLF. In addition, miR-6515-5p may be a prognostic marker in ARDS patients suffering from PLF.
These data identified the abnormal expression of miR-6515-5p in ARDS and PLF, and implied a potential clinical early diagnostic and prognostic marker in ARDS suffering from PLF.
急性呼吸窘迫综合征（ARDS）的高死亡率与肺纤维化（PLF）密切相关，肺纤维化程度影响ARDS的预后。大量研究表明，微小RNA（miRNA）在各种肺部疾病（如ARDS和PLF）的发病机制中表达异常。本研究旨在探讨血清miR-6515-5p在ARDS合并PLF中的表达及其临床意义。
采用逆转录定量聚合酶链反应（RT-qPCR）分析检测合并或未合并PLF的ARDS患者血清标本中miR-6515-5p水平。绘制受试者工作特征（ROC）曲线评估miR-6515-5p的诊断价值。进行逻辑回归分析以分析与ARDS患者发生PLF相关的危险因素。绘制Kaplan-Meier曲线评估miR-6515-5p对ARDS合并PLF患者预后的预测价值。进行多变量COX回归分析以确定与预后相关的PLF相关危险因素。
ARDS患者血清miR-6515-5p表达下调，尤其是合并PLF的患者。miR-6515-5p表达可区分ARDS患者与健康个体，并与PLF的发生有关。大多数miR-6515-5p表达低的患者用力肺活量（FVC）和肺一氧化碳弥散量（DLCO）低，默里评分和急性生理与慢性健康状况评分系统II（APACHE II）评分高。此外，miR-6515-5p表达在区分合并PLF的ARDS患者和未合并PLF的患者方面具有一定的高价值。此外，miR-6515-5p可能是ARDS合并PLF患者的预后标志物。
这些数据确定了miR-6515-5p在ARDS和PLF中的异常表达，并暗示其可能是ARDS合并PLF的潜在临床早期诊断和预后标志物。
